首页> 外文OA文献 >Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study

【2h】

Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study

机译：持续治疗新型抗糖尿病药物（二肽基肽酶-4抑制剂，钠葡萄糖共转运蛋白-2抑制剂和胰高血糖素样肽-1受体激动剂），其患有2型糖尿病的人：全国范围内的队列研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
György Jermendy; Zoltán Kiss; György Rokszin; Zsolt Abonyi-Tóth; István Wittmann; Péter Kempler;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study [J] . Gy?rgy Jermendy, Zoltán Kiss, Gy?rgy Rokszin, Diabetes therapy . 2018,第5期

机译：在2型糖尿病患者中持续使用新型抗糖尿病药物（二肽基肽酶4抑制剂，钠葡萄糖共转运蛋白2抑制剂和胰高血糖素样肽1受体激动剂）进行的全国性队列研究
2. Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning [J] . Yamada Tomohide, Iwasaki Kosuke, Maedera Shotaro, Current medical research and opinion . 2020,第3期

机译：使用钠 - 葡萄糖共转运蛋白-2抑制剂，二肽基肽酶-4抑制剂或胰高血糖素类肽-1受体激动剂的心肌梗死：基于深度神经网络的机器学习的比例危害分析
3. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors [J] . Ohki Takamasa, Isogawa Akihiro, Toda Nobuo, Clinical drug investigation . 2016,第4期

机译：依格列净，一种钠-葡萄糖共转运蛋白2抑制剂，对二型糖尿病非酒精性脂肪性肝病患者的二线治疗无效，这些患者对包括胰高血糖素样肽-1类似物在内的基于肠促胰岛素的疗法无反应和Depteptidyl Peptidase-4抑制剂
4. Fragment-Based Drug Design to Discover Novel Inhibitor of Dipeptidyl Peptidase-4 (DPP-4) as a Potential Drug for Type 2 Diabetes Therapy [C] . Eka Gunarti Ningsih, Muhammad Fauzi Hidayat, Usman Sumo Friend Tambunan International work-conference on bioinformatics and biomedical engineering . 2019

机译：基于片段的药物设计，发现二肽基肽酶-4（DPP-4）的新型抑制剂作为2型糖尿病治疗的潜在药物
5. Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study [O] . György Jermendy, Zoltán Kiss, György Rokszin, 2018

机译：在2型糖尿病患者中持续使用新型抗糖尿病药物（二肽基肽酶4抑制剂钠-葡萄糖共转运蛋白2抑制剂和胰高血糖素样肽1受体激动剂）进行的全国性队列研究
6. Comment on “Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study” and a case report of glucagon-like peptide-1 receptor agonist–induced bullous pemphigoid [O] . Zachary Schwager, Anar Mikailov, Adam D. Lipworth 2019

机译：评论“除了二肽基肽酶-4抑制剂以外的口腔糖尿病药物与大疱性毒性的情况无关：芬兰国家病例对照研究”和胰高血糖素肽-1受体激动剂诱导的大疱性大疱性Pemphigoid的病例报告

Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study

著录项

相似文献

相关主题

期刊订阅